{
  "docId": "019de075-814d-76ed-b6e6-6e437a6b6631",
  "docSlug": "56480dbdf83cce5ae4f2fad948f0ee58",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 26 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 26,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a bulleted list format to outline specific program milestones for five different assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-814d-76ed-b6e6-6e437a6b6631/25",
  "deckHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631",
  "deckJsonHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631.json",
  "deckAnchorHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.1,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "disclaimer",
      "text": "* Anticipated timing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "652bfa36-e36a-4089-8e57-7abcfaca2a7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.95,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "list",
      "text": "XACIATO (clindamycin phosphate) vaginal gel, 2% - First commercial sale in 2023; Ovaprene (hormone-free monthly contraception) - Pivotal Phase 3 subject enrollment to begin 4Q-2023; Sildenafil Cream, 3.6% (FSAD/FSIAD) - Activities related to psychometric analyses; DARE-PDM1 (primary dysmenorrhea) - Phase 1 study topline data 2023; IND related activities for DARE-HRT1 and DARE-VVA1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f65969b7-0fe1-493d-9333-755704a3fe09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.04
      },
      "kind": "title",
      "text": "Daré – Working to Accelerate Innovation in Women's Health",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9622b64b-61cf-4490-bea0-71211cfcc8e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "title",
      "text": "Upcoming Program Milestones*:",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83168e04-beaf-44d9-871d-4f0533393497",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}